Indeed, we apply ATR inhibitor AZD6738 to ocular cells for the first time and found that it affects HConFs through a dual pharmacological mechanism of CHK1/P53 and PI3K/AKT pathways, which differs from previously observed effects of AZD6738 on several cancer cells. Here, ATR is linked to cancer.